Boron Supplementation Inhibits the Growth and Local Expression of IGF-1 in Human Prostate Adenocarcinoma (LNCaP) Tumors in Nude Mice

Abstract

Prostate-specific antigen (PSA) is a serine protease and one of the most abundant proteins secreted by the human prostate epithelium. PSA is used as a well-established marker of prostate cancer. The involvement of PSA in several early events leading to the development of malignant prostate tumors has made it a target for prevention and intervention. It is thought that PSA cleaves insulin-like growth factor binding protein-3 (IGFBP-3), providing increased local levels of IGF-1, leading to tumor growth. Separately, there are data that suggest an enzymatic regulatory role for dietary boron, which is a serine protease inhibitor. In this study we have addressed the use of boric acid as a PSA inhibitor in an animal study. We have previously reported that low concentrations (6 ug/mL) of boric acid can partially inhibit the proteolytic activity of purified PSA towards a synthetic fluorogenic substrate. Also, by Western blot we have followed the degradation of fibronectin by enzymatically active PSA and have found significant inhibition in the presence of boric acid. We proposed that dietary supplementation with boric acid would inhibit PSA and reduce the development and proliferation of prostate carcinomas in an animal model. We tested this hypothesis using nude mice implanted subcutaneously with LNCaP cells in Matrigel. Two groups (10 animals/group) were dosed with boric acid solutions (1.7, 9.0 mgB/kg/day) by gavage. Control group received only water. Tumor sizes were measured weekly for 8 weeks. Serum PSA and IGF-1 levels were determined at terminal sacrifice. The size of tumors was decreased in mice exposed to the low and high dose of boric acid by 38% and 25%, respectively. Serum PSA levels decreased by 88.6% and 86.4%, respectively, as compared to the control group. There were morphological differences between the tumors in control and boron-dosed animals, including a significantly lower incidence of mitotic figures in the boron-supplemented groups. Circulating IGF-1 levels were not different among groups, though expression of IGF-1 in the tumors was markedly reduced by boron treatment, which we have shown by immunohistochemistry. These data indicate that low-level dietary boron supplementation reduced tumor size and content of a tumor trophic factor, IGF-1.This promising model is being evaluated in further studies.

Keywords

Prostate cancer LNCaP cell line boron dietary supplementation serine protease chemoprevention.

References

Bauer, C.A. , and G. Pettersson (1974). “Effect of Boric Acid on the Catalytic Activity of Streptomyces griseus Protease.” Eur J Biochem 45: 473—7.

Blutt, S.E. , T.C. Polek , L.V. Stewart , M.W. Kattan , and N.L. Weigel (2000). “A Calcitriol Analogue, EB1089, Inhibits the Growth of LNCaP Tumors in Nude Mice.” Cancer Res 60: 779—82.

Bylund, A. , J.X. Zhang , A. Bergh , J.E. Damber , A. Widmark , A. Johansson , H. Adlercreutz , P. Aman , M.J. Sheperd , and G. Hallmans (2000). “Rye Bran and Soy Protein Delay Growth and Increase Apoptosis of Human LNCaP Prostate Adenocarcinoma in Nude Mice.” Prostate 42: 304—14.

Chapin, R.E. , W.W. Ku , M.A. Kenney , and H. McCoy (1998). “The Effects of Dietary Boric Acid on Bone Strength in Rats.” Biol Trace Elem Res 66: 395—9.

Cohen, P. , H.C.B. Graves , D.M. Peehl , M. Kamarei , L.C. Giudice , and R.G. Rosenfeld (1992). “Prostate-Specific Antigen (PSA) is an Insulin-Like Growth Factor Binding Protein-3 Protease Found in Seminal Plasma.” J Clin End Met 75: 1046—53.

Dixon, D. , H. He , and J.K. Haseman (2000). “Immunohistochemical Localization of Growth Factors and their Receptors in Uterine Leiomyomas and Matched Myometrium. ” Environmental Health Perspectives 108: 795— 802.

Gallardo-Williams, M.T. , R.R. Maronpot , R.N. Wine , S.N. Brunssen , and R.E. Chapin (2003). “Inhibition of the Enzymatic Activity of Prostate-Specific Antigen by Boric Acid and 3-Nitrophenyl Boronic Acid. The Prostate. In press.

Grimberg, A. and P. Cohen (2000). “Role of Insulin-Like Growth Factors and their Binding Proteins in Growth Control and Carcinogenesis. ” J Cell Physiol 183: 1—9.

Hunt, C.D. (1998). “Regulation of Enzymatic Activity. One Possible Role of Dietary Boron in Higher Animals and Humans.” Biol Trace Elem Res 66: 205—25.

10.

Hunt, C.D. and J.P. Idso (1999). “Dietary Boron as a Physiological Regulator of the Normal Inflammatory Response: A Review and Current Research Progress .” Trace Elem Exper Med 12: 221—33.

11.

Karr, J.F. , J.A. Kantor , P. Horan Hand , D.L. Eggensperger , and J. Schlom (1995). “The Presence of Prostate-Specific Antigen-Related Genes in Primates and the Expression of Recombinant Human Prostate-Specific Antigen in a Transfected Murine Cell Line.” Cancer Res 55: 2455—62.

12.

Ku, W.W. and R.E. Chapin (1994). “Mechanism of the Testicular Toxicity of Boric Acid in Rats.” Env Health Persp 102 (supp): 99—105.

13.

Lilja, H. , A. Christensson , U. Dahlen , M.T. Matikainen , O. Nilsson , K. Pettersson , and T. Lovgren (1991). “Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with Alpha 1-Antichymotrypsin.” Clin Chem 37: 1618—25.

14.

Meacham, S.L. and C.D. Hunt (1998). “Dietary Boron Intakes of Selected Populations in the United States.” Biol Trace Element Res 66: 14.

15.

Oesterling, J.E. (1991). “Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate. ” J Urol 145: 907—23.

16.

Peehl, D.M. (1995). “Prostate Specific Antigen Role and Function .” Cancer 75 (Suppl): 2021—6.

17.

Webber, M.M. , A. Waghray , and D. Bello (1995). “Prostate-Specific Antigen, a Serine Protease, Facilitates Human Prostate Cancer Cell Invasion.” Clin Cancer Res 1: 1089—94.

18.

Yoshida, E. , S. Ohmura , M. Suguki , M. Maruyama , and H. Mihara (1995). “Prostate-Specific Antigen Activates Single-Chain Urokinase-Type Plasminogen Activator.” Int J Cancer 63: 863—5.

19.

Zhang, Z.F. , M.I. Winon , C. Rainey , and C.D. Eckhert (2001). “Boron is Associated with Decreased Risk of Human Prostate Cancer.” FASEB J 15: A1089.

20.

Zou, Z. , A. Anisowicz , M.J.C. Hendrix , A. Thor , M. Neveu , S. Sheng , K. Rafidi , E. Seftor , and R. Sager (1994). “Maspin, a Serpin with Tumor-Suppressing Activity in Human Mammarian Epithelial Cells.” Science 236: 526—9.